Insiders · VRDN

Tomas Kiselak

Director at Viridian Therapeutics, Inc.\DE (VRDN)

Tomas Kiselak has filed 6 insider reports with the SEC since February 2021, as director at Viridian Therapeutics, Inc.\DE (VRDN). The latest filing, on July 2, 2026, reports grant or award at Viridian Therapeutics, Inc.\DE (VRDN).

Filings
6
Companies
1
Bought on market
None
Sold on market
None

Companies where Tomas Kiselak is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Viridian Therapeutics, Inc.\DE logo
VRDN
Viridian Therapeutics, Inc.\DE
Director$30.12Jul 2, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Tomas Kiselak with

Other insiders at the same companies

Questions about Tomas Kiselak

What is Tomas Kiselak's role at Viridian Therapeutics, Inc.\DE?
Tomas Kiselak reports to the SEC as director at Viridian Therapeutics, Inc.\DE (VRDN), according to the latest filing on July 2, 2026.
Has Tomas Kiselak bought or sold stock recently?
No open-market purchases or sales by Tomas Kiselak are on file. The filings report grant or award.
How do I get alerts when Tomas Kiselak files?
Follow Tomas Kiselak on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Tomas Kiselak (SEC CIK 0001830177). Totals count each trade once, skipping amendments whose original is on file, from Feb 8, 2021 on. View on SEC EDGAR